Larbre Virginie, Alyami Mohammad, Mercier Frederic, Vantard Nicolas, Bonnefoy Isabelle, Opsomer Marie-Agnès, Villeneuve Laurent, Bakrin Naoual, Rioufol Catherine, Glehen Olivier, Kepenekian Vahan
Department of Clinical Oncology Pharmacy, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
Department of Surgical Oncology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France
Anticancer Res. 2018 Dec;38(12):6869-6875. doi: 10.21873/anticanres.13062.
BACKGROUND/AIM: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a recent approach for intraperitoneal chemotherapy with promising results for patients with peritoneal metastasis (PM). The aim of this study was to report renal toxicity for patients who received at least 3 repeated PIPAC procedures.
All patients who underwent at least 3 PIPAC cycles of cisplatin (7.5 mg/m) and doxorubicin (1.5 mg/m) for unresectable PM from December 2015 to September 2017, were analysed regarding postoperative renal toxicity.
Among 103 patients registered in a prospective single center database, 43 patients underwent at least 3 PIPAC cycles representing a total of 175 PIPAC. Median age was 59.8 years, 24 (55.8%) patients were female and median BMI was 22.2 kg/m Most common origins of PM were gastric 22 (51.1%) and ovarian 11 (25.6%) cancer. Median peritoneal cancer index (PCI) was 17 (range=5-39). For 39 (90.1%) patients, systemic chemotherapy was performed in addition to PIPAC. Forty-three (100%), 17 (39.5%), 14 (32.5%), 8 (18.6%), 3 (7%), 2 (4.7%) and 2 (4.7%) patients underwent three, four, five, six, seven, eight and nine PIPAC procedures, respectively. Repeated PIPAC did not induce significant acute nor cumulative renal toxicity in any patients.
Repeated PIPAC did not induce clinically relevant renal toxicity. This study confirms the previous published results in a larger group of patients.
背景/目的：腹腔内加压气雾化疗（PIPAC）是一种近期开展的腹腔化疗方法，对腹膜转移（PM）患者显示出有前景的疗效。本研究旨在报告接受至少3次重复PIPAC治疗的患者的肾毒性情况。
分析2015年12月至2017年9月间，所有因不可切除的PM接受至少3个顺铂（7.5mg/m）和多柔比星（1.5mg/m）PIPAC周期治疗的患者的术后肾毒性。
在前瞻性单中心数据库登记的103例患者中，43例患者接受了至少3个PIPAC周期，共进行了175次PIPAC治疗。中位年龄为59.8岁，24例（55.8%）为女性，中位BMI为22.2kg/m。PM最常见的原发部位是胃癌22例（51.1%）和卵巢癌11例（25.6%）。中位腹膜癌指数（PCI）为17（范围=5-39）。39例（90.1%）患者除PIPAC外还接受了全身化疗。43例（100%）、17例（39.5%）、14例（32.5%）、8例（18.6%）、3例（7%）、2例（4.7%）和2例（4.7%）患者分别接受了3次、4次、5次、6次、7次、8次和9次PIPAC治疗。重复PIPAC未在任何患者中诱发显著的急性或累积性肾毒性。
重复PIPAC未诱发临床相关的肾毒性。本研究在更大规模的患者群体中证实了先前发表的结果。
